RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.PRNewsWire • 08/01/23
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDAPRNewsWire • 07/31/23
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant ExercisePRNewsWire • 07/25/23
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross ProceedsPRNewsWire • 07/21/23
RedHill Biopharma's stock soars 10% after company gets U.S. funding to develop treatment for radiation sicknessMarket Watch • 07/21/23
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure DevelopmentPRNewsWire • 07/21/23
RedHill Biopharma Announces Q1/2023 Financial Results and Operational HighlightsPRNewsWire • 06/12/23
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyPRNewsWire • 05/15/23
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease WeekPRNewsWire • 05/09/23
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology SettingPRNewsWire • 05/01/23
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsPRNewsWire • 04/28/23
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-RespondersPRNewsWire • 03/21/23
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single InvestorPRNewsWire • 03/09/23
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For DevelopmentAccesswire • 02/28/23
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures ProgramPRNewsWire • 02/28/23
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA PlanAccesswire • 02/16/23
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology SupportPRNewsWire • 02/16/23
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation SyndromePRNewsWire • 02/15/23
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®PRNewsWire • 02/06/23